EHMT2 and neoplasm: This suggests that the effects of BIX-01294 on oncogenic processes are specific and reproducible with other G9A loss-of-function experiments and, together with our previous findings that BIX-01294 can reduce tumor growth in vivo [6], make BIX-01294 and other G9A inhibitors of strong clinical interest as pharmacological agents.